CD34 and cancer: Differential gene expression analysis (Supplementary Table 2) revealed the top-scoring differentially expressed gene of the low EPCAM cluster to be CD70 (adjusted p-value = 1.002e-14)(Figure 2B), which was previously suggested as a therapeutic target for RCC (43), and also top-scoring differentially expressed genes proposed to be associated with cancer stem cells [e.g. CD34, adjusted p-value = 3.163e-14 (44, 45); CD90/THY1, adjusted p-value = 3.247e-11 (46)].